Cyclacel Pharmaceuticals, Inc. reported earnings results for the third quarter ended September 30, 2022. For the third quarter, the company reported net loss was USD 5.1 million compared to USD 4.99 million a year ago. Basic loss per share from continuing operations was USD 0.42 compared to USD 0.54 a year ago.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
2 USD | -0.50% | -7.16% | -26.22% |
14/05 | Cyclacel Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
14/05 | Transcript : Cyclacel Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 14, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-26.22% | 29.41L | |
+8.66% | 12TCr | |
+9.31% | 10TCr | |
-12.34% | 2.27TCr | |
+2.21% | 2.18TCr | |
-10.88% | 1.82TCr | |
-41.90% | 1.65TCr | |
-16.74% | 1.6TCr | |
+1.60% | 1.41TCr | |
+18.03% | 1.07TCr |
- Stock Market
- Equities
- CYCC Stock
- News Cyclacel Pharmaceuticals, Inc.
- Cyclacel Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2022